Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors.

Matthew R SchuelkeJustin H GundelachMatt CoffeyEmma WestKaren ScottDerek R JohnsonAdel SamsonAlan A MelcherRichard G VileRichard J Bram

Published in: Neuro-oncology advances (2022)

Sargramostim/pelareorep was administered to pediatric patients with recurrent or refractory high-grade brain tumors. Hyponatremia was the only dose limiting toxicity (DLT), though maximum tolerated dose (MTD) was not determined.

Keyphrases

high grade
low grade
clinical trial
oxidative stress
phase iii
stem cells
heart failure
phase ii
atrial fibrillation
replacement therapy